Satraplatin for Patients With Metastatic Breast Cancer (MBC)

Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)

To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.

This is a Phase II open label, nonrandomized study for patients with metastatic breast cancer.

WHAT IS SATRAPLATIN:

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

1. Has cytologically or pathologically confirmed breast cancer that is metastatic
2. Must have had prior HerceptinÒ therapy if patient has HER2+ (overexpressing) breast cancer. HER2 is considered overexpressed if it is 3+ by IHC or if the gene is amplified by Flourescence in situ hybridization (FISH)
3. Has had no more than 1 prior chemotherapy regimen for MBC
4. Has had no prior platinum-based therapy
5. Has an ECOG Performance Status (PS) 0-2